Melanotan II and the Number Nobody Puts on the Label: Zero

A lot of people assume Melanotan II must be legitimate if you can order it online so easily. It isn’t, and the number that proves it is zero. Zero regulators, out of the four major ones that matter to most readers of this piece (the FDA, the UK’s MHRA, the EU’s EMA, Australia’s TGA), have approved it for use in a human body. Not one. And yet the checkout page works fine, the package arrives, and somewhere a marketing copywriter is calling it “research grade” with a straight face. That gap, between zero approvals and one very functional shopping cart, is the whole story. Everything else is commentary.

The argument: a label is not a license

I want to be precise about what’s actually happening, because “illegal” and “unapproved” get used interchangeably online and they are not the same thing.

Melanotan II never finished clinical development. No trial data cleared the bar that would let a regulator say “yes, this is safe and effective enough to sell as medicine.” That’s not a technicality, it’s the entire reason it sits where it sits. A 2009 BMJ editorial was already flagging these products as unlicensed substances being sold straight to the public online, back when the internet still felt new for this kind of thing (Evans-Brown et al., 2009, BMJ). Seventeen years later, nothing about that status has moved in the compound’s favor.

So how do you still buy it in three clicks? Three words: “research use only.” Sometimes swapped for “not for human consumption.” It’s a legal fiction that works because it shifts the framing from “we sell an injectable drug to consumers” to “we sell a chemical to laboratories,” and as long as the seller doesn’t explicitly say otherwise, they’ve built themselves some distance from what happens after the package leaves the warehouse. Nobody believes the powder is going into a beaker. The label isn’t describing the transaction, it’s insuring the seller against it.

Run the logic forward and you get an uncomfortable asymmetry. The label protects the seller. It does nothing for you. It doesn’t mean anyone verified the dose, the purity, or the sterility of what’s in the vial, and a 2017 review of these compounds spelled out exactly that danger, unlicensed product of unknown quality, injected anyway (Habbema et al., 2017, International Journal of Dermatology). You take on all the risk. The seller takes on none of the liability. That’s not a gray area, that’s just how the trade is structured.

The counterpoint: “but compounding is legal, isn’t it?”

This is where I’d push back on myself if I were reading this cold, because it’s the objection I hear most. Compounding pharmacies are real, legitimate parts of the US medical system. A 503A pharmacy compounds for an individual patient against a prescription. A 503B facility compounds at larger scale under stricter manufacturing rules. Both exist, both are lawful, both matter.

But compounding isn’t a switch you flip to legalize an ingredient. It’s a process for preparing medications from active ingredients that are already suited to compounding, dispensed by a licensed pharmacy against a prescription from a clinician who has actually looked at the patient. Melanotan II doesn’t have the approved-drug status that normally anchors that process, and its safety record (more on that below) gives a responsible prescriber real reasons for caution. So “it’s compounded, therefore it’s legal” doesn’t hold up the way people want it to. What a genuinely supervised model changes is not the legal status of the molecule, it’s who is accountable for what lands in your fridge. A licensed clinician screening you and a licensed pharmacy involved in fulfillment is a real, meaningful difference from an anonymous vial in a padded envelope. It’s just not the same claim as “this is an approved drug.”

There’s a second counterpoint worth naming too, because vendors lean on it constantly: the “but there’s an approved version” argument. There is, technically, an approved melanocortin drug: afamelanotide, sometimes marketed as Melanotan I. Different molecule, more selective, and approved for exactly one thing: erythropoietic protoporphyria, a rare inherited condition where sunlight causes severe pain, delivered as a clinician-placed implant, not a self-injected peptide (Kim and Garnock-Jones, 2016, American Journal of Clinical Dermatology). One approved use. One rare disease. One controlled delivery method. That’s the entire scope of the approval, and it has nothing to do with tanning or with Melanotan II. When a seller blurs the two, they’re borrowing legitimacy that doesn’t transfer.

What the loophole actually costs you

I think the “research use only” framing survives because people mentally file it under “technically fine, morally gray.” I’d reframe it as a cost question instead. What does the loophole actually cost the buyer?

First, there’s no quality floor. Nobody inspected the vial. Second, there’s no recourse. If customs seizes a shipment of an unapproved drug labeled “not for human consumption,” you have no licensed party to complain to, because on paper, nobody sold you a drug at all. Third, and this is the one people skip, you’re handing payment details and a shipping address to an operation that exists specifically because it sits outside the regulated system. None of that shows up on the product page. All of it is part of the actual transaction.

And underneath all of it sits the reason the approval never came in the first place: the human data is mostly case reports of harm, not trials of benefit. A fair-skinned young woman developed a melanoma after using Melanotan II to deepen a sunbed tan (Hjuler and Lorentzen, 2014, Dermatology). The original human study confirming its erection-inducing effect also logged frequent nausea, severe at higher doses (Wessells et al., 2000, International Journal of Impotence Research). Zero approvals isn’t bureaucratic inertia. It’s a number with case reports underneath it.

If you’re a tested athlete, add one more line to the ledger. Melanotan II is a melanocortin receptor agonist, and WADA’s catch-all provision for non-approved substances treats exactly this category, pharmacologically active, cleared nowhere, with suspicion. No approval anywhere in the world means it lands squarely in the prohibited category by default. That’s not a compound worth gambling a season on. Check the current WADA list yourself rather than trusting a forum thread.

Where that leaves you

So: zero regulatory approvals, one very effective labeling loophole, and a literature full of warnings rather than reassurance. That’s the honest shape of it. Compounding doesn’t erase the zero. The approved cousin doesn’t lend it legitimacy. And the ease of the checkout page is doing a lot of work to hide all three of those facts from you.

If you’ve weighed that and still want to engage with this compound, the more defensible path is the one where a licensed clinician actually looks at you first and a licensed pharmacy is in the loop, rather than a stranger mailing a vial with a disclaimer attached. FormBlends operates that kind of physician-supervised model. To be clear, that supervision doesn’t turn Melanotan II into an approved drug, compounded medications prepared by licensed pharmacies for an individual patient are still not FDA-approved products. What changes is accountability: someone screened you, someone is reachable if something goes wrong, instead of nothing and no one. For a compound with this particular safety record, that’s not a small difference.

Questions I keep getting asked

Is Melanotan II legal to buy in the US in 2026?

No regulator anywhere, US, UK, EU, or Australia, has approved it for human use, so marketing it as a treatment isn’t lawful. What lets it keep selling is the “research use only” or “not for human consumption” label, which moves the product outside the medicines framework rather than making the sale legitimate. Buying it usually won’t trip a possession statute the way a scheduled drug would, but you’re still purchasing an unapproved drug under a labeling fiction, with the legal and quality risk resting on you.

Does “research use only” mean the vial was actually tested?

No. Think of it as a liability shield pointed away from the seller, not a quality claim about the contents. Nobody verified the dose, the purity, or the sterility, and if the powder turns out mislabeled or contaminated, you have no licensed party to hold accountable.

Is Melanotan II the same thing as the approved drug afamelanotide?

No, and any vendor implying otherwise is doing marketing, not stating fact. Afamelanotide (sometimes called Melanotan I) is a different, more selective molecule approved for exactly one rare condition, erythropoietic protoporphyria, delivered as a clinician-placed implant. That approval doesn’t stretch to cosmetic tanning or to Melanotan II in any form.

Can a compounding pharmacy make Melanotan II legal?

Not in the sense of turning it into an approved drug. Compounding under 503A or 503B rules works with ingredients suited to the process and dispensed against a prescription, and Melanotan II lacks the approved status that normally underpins that. A properly supervised model changes who’s accountable for what you receive, a licensed clinician and pharmacy versus an anonymous shipper, but it doesn’t make the compound proven or legally equivalent to an approved medicine.

Will Melanotan II show up as a doping violation?

Assume yes. As a melanocortin receptor agonist with zero approvals anywhere, it falls under the anti-doping rules banning non-approved pharmacologically active substances. If you’re tested, treat it as off-limits and verify against the current WADA Prohibited List rather than a forum post.

What actually happens to people who use it?

The published record leans heavily toward harm rather than benefit, which is a large part of why approval never came. There’s a case of melanoma in a fair-skinned young woman who used it alongside sunbed tanning, and an early human trial recorded frequent nausea, severe at higher doses. Given that purity and dosing in this market are unverified, real-world outcomes could easily run worse than what the published reports capture.

Does Melanotan II work without any sun exposure?

It can nudge melanin production on its own, and some users do report a baseline darkening with zero sun. But the effect is consistently reported as stronger when paired with UV, sun or a tanning bed. The peptide is signaling the skin to make more melanin, while UV still acts as the amplifier on top of that signal. Without sun, results tend to be modest and vary a lot by skin type.

Does Melanotan II change eye color?

I haven’t found reliable evidence that it does. Some users describe their irises looking darker, but the iris runs on a different population of melanocytes than skin does, and no controlled study confirms a consistent, lasting shift. What is documented is increased pigmentation in existing moles and nevi, which is a safety flag, not a cosmetic bonus. New or changing eye spots warrant an ophthalmologist, not a forum post.

Where do people actually buy it, and how do the risks stack up?

Most of the supply runs through unregulated research-chemical sites and gray-market vendors, no inspection, no accountability, real contamination and mislabeling risk. A small number of physician-supervised compounding pharmacies, FormBlends among them, work inside a legal, quality-controlled framework, though your access depends heavily on jurisdiction and having a prescribing clinician involved. Buying from an unverified vendor is, by almost any measure, the riskiest of the available routes.

How much do people typically use, and why is that a hard question to answer responsibly?

There’s no established safe or approved human dose, period. Online communities often cite loading doses around 0.5 to 1 mg injected subcutaneously, but that’s forum lore, not trial data. The peptide is potent at the melanocortin receptor, and nausea, flushing, and spontaneous erections show up even at low amounts. Without pharmaceutical-grade material and a clinician watching, every dose is a guess with real variance built in.

References (primary sources)

1. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ, 2009. PMID 19224885.
2. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 2017. PMID 28266027.
3. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology, 2016. PMID 26979527.
4. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology, 2014. PMID 24355990.
5. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID 11035391.